Mibefradil is a Ca 2ϩ channel antagonist that inhibits both Ttype and high-voltage-activated Ca 2ϩ channels. We previously showed that block of high-voltage-activated channels by mibefradil occurs through the production of an active metabolite by intracellular hydrolysis. In the present study, we modified the structure of mibefradil to develop a nonhydrolyzable analog, (1S, 2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride , that exerts a selective inhibitory effect on T-type channels. The acute IC 50 of NNC 55-0396 to block recombinant ␣ 1 G T-type channels in human embryonic kidney 293 cells was ϳ7 M, whereas 100 M NNC 55-0396 had no detectable effect on high-voltage-activated channels in INS-1 cells. NNC 55-0396 did not affect the voltage-dependent activation of T-type Ca 2ϩ currents but changed the slope of the steady-state inactivation curve. Block of T-type Ca 2ϩ current was partially relieved by membrane hyperpolarization and enhanced at a high-stimulus frequency. Washing NNC 55-0396 out of the recording chamber did not reverse the T-type Ca 2ϩ current activity, suggesting that the compound dissolves in or passes through the plasma membrane to exert its effect; however, intracellular perfusion of the compound did not block T-type Ca 2ϩ currents, arguing against a cytoplasmic route of action. After incubating cells from an insulin-secreting cell line (INS-1) with NNC 55-0396 for 20 min, mass spectrometry did not detect the mibefradil metabolite that causes L-type Ca 2ϩ channel inhibition. We conclude that NNC 55-0396, by virtue of its modified structure, does not produce the metabolite that causes inhibition of Ltype Ca 2ϩ channels, thus rendering it more selective to T-type Ca 2ϩ channels.
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currents but changed the slope of the steady-state inactivation curve. Block of T-type Ca 2ϩ current was partially relieved by membrane hyperpolarization and enhanced at a high-stimulus frequency. Washing NNC 55-0396 out of the recording chamber did not reverse the T-type Ca 2ϩ current activity, suggesting that the compound dissolves in or passes through the plasma membrane to exert its effect; however, intracellular perfusion of the compound did not block T-type Ca 2ϩ currents, arguing against a cytoplasmic route of action. After incubating cells from an insulin-secreting cell line (INS-1) with NNC 55-0396 for 20 min, mass spectrometry did not detect the mibefradil metabolite that causes L-type Ca 2ϩ channel inhibition. We conclude that NNC 55-0396, by virtue of its modified structure, does not produce the metabolite that causes inhibition of Ltype Ca 2ϩ channels, thus rendering it more selective to T-type Ca 2ϩ channels.
Voltage-gated Ca 2ϩ channels are transmembrane proteins involved in the regulation of cellular excitability and intracellular Ca 2ϩ signaling. Calcium channels have been divided into various categories based on functional and pharmacological criteria. High-voltage-activated (HVA) channels, which have been further subdivided into L-, N-, P/Q-, and R-types, require strong depolarizations for activation, whereas lowvoltage-activated or T-type channels activate over a much more negative voltage range and exhibit unique inactivation and deactivation kinetics (Armstrong and Matteson, 1985; Catterall, 1998; Perez-Reyes, 1998) . The main structural component of the voltage-gated calcium channel is the ␣ 1 subunit, which forms the pore and the channel gates. Molecular cloning has identified 10 ␣ 1 subtypes. ␣ 1 A-␣ 1 E and ␣ 1 S encode HVA channels, whereas ␣ 1 G-␣ 1 I encode T-type channels. Pharmacological agents that act selectively on ␣ 1 subtypes have been key in studying calcium channel function in many physiological systems; however, a selective antagonist of T-type Ca 2ϩ channels is not yet available. Mibefradil, a tetralol derivative chemically distinct from other Ca 2ϩ channel antagonists, has been reported to block T-type Ca 2ϩ channel currents in many tissues, including heart (Madle et al., 2001 ), brain (McDonough and Bean, 1998) , and vascular smooth muscle (Bian and Hermsmeyer, 1993; Mishra and Hermsmeyer, 1994; Schmitt et al., 1995) . Mibefradil was also reported to block HVA Ca 2ϩ channels, including ␣ 1 A, ␣ 1 B, ␣ 1 C, and ␣ 1 E (Bezprozvanny and Tsien, 1995; Jiménez et al., 2000) . We previously demonstrated that mibefradil potently blocked HVA Ca 2ϩ channels in a rat insulin-secreting cell line (INS-1 cells) via a mechanism involving intracellular hydrolysis of mibefradil to produce an active metabolite .
The cardiovascular effects of mibefradil are interesting; for instance, it decreases heart rate without a negative inotropic effect (Osterrieder and Holck, 1989; Cremers et al., 1997) , and its action is not associated with the reflex activation of neurohormonal and sympathetic systems (Ernst and Kelly, 1998) . These properties differ from other clinically important Ca 2ϩ antagonists such as nifedipine, diltiazem, and verapamil, which in the heart selectively inhibit L-type (␣ 1 C) Ca 2ϩ channels. However, it is unclear whether the unique effects of mibefradil are caused by the blockade of T-type Ca 2ϩ channels since mibefradil also blocks the L-type Ca 2ϩ currents in the cardiomyocytes (Leuranguer et al., 2001) . Therefore, identifying a more selective T-type Ca 2ϩ channel antagonist will be useful for the study of cardiac voltagegated calcium channels and may promote the development of a new class of therapeutically beneficial compounds.
In a previous study, we demonstrated that hydrolysis of the ester side chain of mibefradil resulted in a compound (des-methoxyacetyl mibefradil or Ro 40-5966) that exhibited an L-type Ca 2ϩ channel-specific inhibitory effect . We thus proposed that modifications in this ester side chain, which decreased hydrolysis, might result in compounds with a lower potency in blocking L-type Ca 2ϩ channels and selective action on T-type channels. To test this hypothesis, we examined the effects of several novel mibefradil derivates on T-type and HVA Ca 2ϩ currents in wholecell voltage-clamp recordings. We used HEK 293 cells stably transfected with the ␣ 1 G subtype of T-type Ca 2ϩ channel (HEK/␣ 1 G) and INS-1 cells to test the effects of our new compounds on T-type and HVA Ca 2ϩ channels, respectively. INS-1 cells express a variety of HVA Ca 2ϩ currents, including P/Q-, N-, L-, and R-types (Horvath et al., 1998) , with ␣ 1 D contributing most of the currents (Liu et al., 2002; Huang et al., 2004) .
Materials and Methods
Cell Culture. INS-1 cells, an insulin-secreting cell line derived from rat pancreatic ␤-cells (Asfari et al., 1992) were cultured in RPMI 1640 medium containing 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 50 M mercaptoethanol in an atmosphere of 5% CO 2 in air at 37°C for 2 to 5 days before recording.
Creation of HEK 293 Cell Lines Stably Expressing Recombinant T-Type Ca
2؉ Channels. An ␣ 1 G cDNA originally cloned from rat pancreatic ␤-cells (Zhuang et al., 2000) in vector pcDNA3.1 hygro(Ϫ) (Invitrogen, Carlsbad, CA) was transfected into HEK cells using the FuGENE kit (Roche Diagnostics, Indianapolis, IN). Cell lines stably expressing Ca v 3.1 were obtained after transfection using standard cell cloning techniques (Freshney, 1983) . HEK 293 cells stably transfected with ␣ 1 G cDNA (HEK 293/␣ 1 G) were incubated in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, and 0.5 mg/ml hygromycin-B in an atmosphere of 5% CO 2 in air at 37°C for 2 to 5 days before recording.
Electrophysiological Recording. Whole-cell recordings were carried out by the standard "giga-seal" patch-clamp technique. The whole-cell recording pipettes were made of hemocapillaries (Warner Instrument, Hamden, CT), pulled by a two-stage puller (PC-10; Narishige, Greenvale, NY), and heat-polished with a microforge (MF-200; World Precision Instruments, Sarasota, FL) before use. Pipette resistance was in the range of 2 to 5 M⍀ in our internal solution. The recordings were performed at room temperature (22-25°C). Electrical currents were recorded using an EPC-9 patchclamp amplifier (HEKA, Lambrecht/Pfalz, Germany) and filtered at 2.9 kHz. Data were acquired with PULSE/PULSEFIT software (HEKA). Voltage-dependent currents were corrected for linear leak and residual capacitance by using an on-line P/n subtraction paradigm. In the whole-cell configuration, T-type Ca 2ϩ currents were recorded at Ϫ20 or Ϫ10 mV when the holding potential was Ϫ70 mV. The HVA Ca 2ϩ current was measured at 10 mV, with a holding potential of Ϫ40 mV.
Solutions. The extracellular solution used in the whole-cell Ca 2ϩ current recording contained 10 mM CaCl 2 , 110 mM tetraethylammonium-Cl, 10 mM CsCl, 10 mM HEPES, 40 mM sucrose, 0.5 mM 3,4-diaminopyridine, pH 7.3. The intracellular solution contained 130 mM N-methyl-D-glucamine, 20 mM EGTA (free acid), 5 mM 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetate, 10 mM HEPES, 6 mM MgCl 2 , and 4 mM Ca(OH) 2 , with pH adjusted to 7.4 with methanesulfonate. Mg-ATP (2 mM) was included in the pipette solution to minimize rundown of L-type Ca 2ϩ currents. For perforated-patch experiments, 200 g/ml nystatin was used. The pipette was filled with nystatin-containing intracellular solution, and gentle suction was used to achieve gigaohm resistance. The access resistance gradually decreased within 5 min after the gigaohm-seal formation, and then currents were recorded after stabilization. The extracellular solution contained 26 mM sucrose, 130 mM tetraethylammonium-Cl, 10 mM HEPES, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , pH 7.3. The pipette solution contained 65 mM CsOH, 65 mM Cs-methanesulfonate, 20 mM sucrose, 10 mM HEPES, 10 mM MgCl 2 , and 1 mM Ca(OH) 2 , with pH 7.4.
Mass Spectrometric Analysis. Mass spectrometric analysis was performed on a PerSeptive Voyager-DE MALDI-TOF instrument (Applied Biosystems, Foster City, CA). Cultured INS-1 cells were treated with 20 M NNC 55-0396 for various lengths of time under each experimental condition. After incubation, cells were washed with PBS three times, scraped into Eppendorf tubes with 1 ml of PBS, and centrifuged at 1000g for 5 min. The cell pellets were collected and redissolved by sonication (10 s) in 0.5 ml of PBS for mass spectrometric analysis. The sample was taken up in ␣-cyano-4-hydroxcinnamic acid (Aldrich, Milwaukee, MI), which was used as the matrix. Ten microliters of each sample were mixed with 70 l of the matrix. One microliter of the mixture was spotted on a plate for analysis on the MALDI-TOF instrument. Several positive ion spectra were recorded in the mass range m/z 820 to 99 at a mass resolution of 1000 and a scan speed of 2 s/decade. For NNC 55-0396, m/z 492 was the dominant ion (M ϩ H). For calibration, a standard solution of 50 M NNC 55-0396 was subjected to mass spectrometric analysis. The relative amount of NNC 55-0396 was determined by calibrating the intensities of NNC 55-0396 with the intensity of standard solution.
Statistics and Curve Fitting. Nonlinear regression analysis was used to fit concentration-response data to a sigmoid relationship, Y ϭ 100/(1 ϩ 10ˆ((log IC 50 Ϫ X) slope), where slope is the Hill slope parameter, IC 50 is the concentration producing 50% blockage, and X is the drug concentration. Voltage-dependent activation and steady-state inactivation curves were generated by normalizing the currents with the maximal amplitude in each cell and fitting the data with the Boltzmann equation, 1/(1 ϩ exp((V Ϫ V 1/2 )/k), where k represents the slope and V 1/2 represents the voltage corresponding to half-activation of the channels. Student's t test was used to compare V 1/2 and k values determined from fits of the data with this equation. The data fitting and statistical analysis were performed with Prism version 4 (GraphPad Software, San Diego, CA). In the figures where the data are presented as symbols and error bars, the values are mean Ϯ S.E.M.
General Chemical Procedure. Reagents, starting materials, and solvents were purchased from common commercial suppliers and were used as received. All dry solvents were dried over molecular sieves (0.3 or 0.4 nm). Evaporation was carried out on a rotary evaporator at bath temperatures Ͻ40°C and under appropriate vacuum. Flash chromatography was carried out on a Biotage FLASH 40 (Biotage AB, Uppsala, Sweden) using Biotage FLASH columns (KP-SIL 60 Å particle size, 32-63 M). Melting points were determined with a Bü chi B545 apparatus (Bü chi, Flawil, Switzerland) and are uncorrected. Proton NMR spectra were recorded at ambient temperature using a Bruker AVANCE DPX 200 (Bruker, Newark, DE) (200 MHz) and DPX 300 (300 MHz), with tetramethylsilane as an internal standard for proton spectra. Chemical shifts are given in ppm (␦), and splitting patterns are designated as follows: s, singlet; d, doublet; dd, double doublet; t, triplet; dt, double triplet; q, quartet; quint, quintet; m, multiplet; and br, broad. The 70-electron-volt EI solid mass spectra were recorded on a Finnigan MAT TSQ 70 mass spectrometer (Thermo Finnigan, San Jose, CA). Reactions were followed by thin layer chromatography performed on silica gel 60 F254 (Merck, Darmstadt, Germany) or ALUGRAM SIL G/UV 254 (Macherey-Nagel, Dü ren, Germany) thin layer chromatography aluminum sheets.
Synthesis of NNC 55-0396.
,4-tetrahydro-2-naphthyl ester dihydrochloride) (mibefradil, 0.570 g) in ethanol (96%, 5 ml) and aqueous sodium hydroxide (1 N, 5 ml) was refluxed for 2 h. The cold reaction mixture was concentrated in vacuo. The residue was partitioned between water and dichloromethane. The aqueous layer was extracted with dichloromethane. The combined organic layers were dried with sodium sulfate and concentrated to give 2- 
,4-tetrahydro-2-naphthalinol (0.110 g) was dissolved in 1 ml of dichloromethane. Diisopropylethylamine (0.045 ml) and 0.071 ml of cyclopropanecarbonyl chloride was added. After stirring for 19 h, the reaction mixture aqueous saturated sodium hydrogencarbonate was added. The aqueous layer was extracted twice with dichloromethane. The combined organic layers were dried with sodium sulfate and concentrated in vacuo. The residue was purified by flash chromatography using dichloromethane/methanol 6:1 as an eluent to give the free base as a syrup. This product was dissolved in ethanol, and aqueous hydrochloride (1 N, 0.38 ml) was added. After stirring for 30 min, the mixture was concentrated. The residue was crystallized from ethyl acetate to give the title compound N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1 N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopro 
Synthesis of (1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-

Results
Synthesis of NNC 55-0396 and Other Mibefradil Analogs. We synthesized three analogs of mibefradil by replacing the ester chain (methoxyacetyl) group NNC 55-0395, NNC 55-0396, and NNC 55-0397 (Fig. 1) . All compounds were synthesized from mibefradil in two steps. Alkaline hydrolysis of mibefradil and subsequent treatment with valeroyl chloride, cyclopropanecarbonyl chloride, and isobutyryl chloride gave the desired compounds NNC 55-0395, NNC 55-0396, and NNC 55-0397 upon workup, respectively.
Pharmacological-Screening Effect of NNC 55-0395, NNC 55-0396, and NNC 55-0397 on T-Type and HVA Ca 2؉ Currents. We used perforated whole-cell patch-clamp to examine the effects of NNC 55-0395, NNC 55-0396, and NNC 55-0397 on HVA Ca 2ϩ current in INS-1 cells. In these experiments, the resting membrane potential was held at Ϫ40 mV to eliminate T-type Ca 2ϩ current. The inhibitory potency of the mibefradil analogs on HVA Ca 2ϩ current was examined at dosages of 0.1, 1, 10, and 100 M approximately 10 min after the drug perfusion. The results showed that both NNC 55-0395 and NNC 55-0397 had an inhibitory effect on HVA Ca 2ϩ currents at 100 M (Fig. 2 , A and C), whereas no inhibition on the HVA Ca 2ϩ current was detected with NNC 55-0396 at the same concentration (Fig. 2B) . jpet.aspetjournals.org
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Next, we determined the effects of NNC 55-0395, NNC 55-0396, and NNC 55-0397 on T-type Ca 2ϩ current. These experiments were conducted by measuring the effects of the compounds on whole-cell current in HEK 293/␣ 1 G cells. The dose-dependent inhibition of compounds NNC 55-0395, NNC 55-0396, and NNC 55-0397 on T-type Ca 2ϩ current was examined at dosages ranging from 1 to 100 M. NNC 55-0396 and NNC 55-0397 blocked more than 50% of the T-type Ca 2ϩ current at 8 M (Fig. 2, E and F) , whereas NNC 55-0395 inhibited less than 50% of the T-type Ca 2ϩ current at 64 M (Fig. 2D) .
Both NNC 55-0395 and NNC 55-0397 blocked HVA Ca 2ϩ channel currents in our screening experiments and were thus eliminated from further characterization. Compound NNC 55-0396, which blocked T-type Ca 2ϩ current but not HVA Ca 2ϩ currents, was selected for subsequent analysis.
Characterization of the Inhibitory Effects of NNC 55-0396 on T-Type Ca
2؉ Current. To further characterize NNC 55-0396, we used whole-cell patch-clamp and a bath perfusion system to examine its dose-dependent effects on T-type and HVA Ca 2ϩ currents. At 8 M, NNC 55-0396 reduced more than 50% of the peak of T-type Ca 2ϩ current compared with the control in HEK 293/␣ 1 G cells (Fig. 3A) ; however, NNC 55-0396 at 100 M did not block the HVA Ca 2ϩ current in INS-1 cells (Fig. 3B ), whereas this HVA Ca 2ϩ current could be inhibited by 10 M nifedipine, a selective L-type Ca 2ϩ channel blocker (Fig. 3C) . Pooled data of the effects of NNC 55-0396 on T-type and HVA Ca 2ϩ currents are shown in Fig. 3D . After bathing HEK 293/␣ 1 G cells with NNC 55-0396 at 8 M or bathing INS-1 cells with NNC 55-0396 at 100 M for over 8 min, T-type Ca 2ϩ currents were inhibited by 60%, whereas no decrease in the HVA Ca 2ϩ current was observed.
The inhibitory potency of NNC 55-0396 on T-type Ca 2ϩ currents in HEK 293/␣ 1 G was also compared with that of mibefradil, as shown in Fig. 3E . By fitting the data with a sigmoid dose-response relationship equation, NNC 55-0396 and mibefradil blocked T-type Ca 2ϩ current with IC 50 values of 6.8 and 10.08, respectively. This result suggests that NNC 55-0396 retains potency similar to mibefradil as an inhibitor of T-type Ca 2ϩ current. Long-term exposure of HEK/␣ 1 G cells to NNC 55-0396 showed a decrease in current density of T-type Ca 2ϩ channels. Using whole-cell patch-clamp, we measured T-type Ca 2ϩ current density in the HEK/␣ 1 G cells that had bathed in the extracellular solutions containing 0, 10, 100, and 1000 nM NNC 55-0396 for 30 to 60 min (Fig. 3F) . All peak-current amplitudes and slow capacitances were obtained during the first minute after breaking in; thus, the effect of the frequency-dependent inhibitory effect was minimal. Our data showed a slow yet more potent inhibitory effect of NNC 55-0396 on the T-type Ca 2ϩ currents. Figure 4A illustrates that there was no significant difference in the conductance-voltage relationship (G/V) curves of T-type Ca 2ϩ currents between the control cells and cells incubated with 8 M NNC 55-0396. The conductance (G) was calculated from the current (I) divided by the driving force (V drive ϭ V membrane Ϫ V reversal ), where the V reversal was hypothetically assigned as 70 mV. Curves were generated by fitting the data with the Boltzmann equation. The V 1/2 and k values are Ϫ32.61 Ϯ 1.0 and 4.16 Ϯ 0.9 for the controls (n ϭ 3) and Ϫ32.12 Ϯ 0.8 and 4.33 Ϯ 0.73 for cells incubated with NNC 55-0396 (n ϭ 3), respectively. The steady-state inactivation curves of T-type Ca 2ϩ current were also generated with the Boltzmann equation (Fig. 4B) . The V 1/2 values are Ϫ59.21 Ϯ 0.38 and Ϫ62.84 Ϯ 0.94 for the controls (n ϭ 4) and cells incubated with NNC 55-0396 (n ϭ 6), respectively. The slope k values are 4.92 Ϯ 0.33 with a 95% confidence interval between 4.16 to 5.69 for the controls and 7.95 Ϯ 0.72 with a 95% confidence interval between 6.31 to 9.58 for cells incubated with NNC 55-0396, respectively. Therefore, the steadystate inactivation curve of T-type Ca 2ϩ current is flattened when NNC 55-0396 is present.
State-Dependent Block of T-Type Ca 2؉ Current by NNC 55-0396. The inhibitory mechanism of NNC 55-0396 on T-type Ca 2ϩ current was further investigated by testing the effect of changing the holding potential and stimulation frequency. As shown in Fig. 5A , in the absence of NNC 55-0396, changing the holding potential from Ϫ120 to Ϫ80 mV did not alter the peak amplitude of T-type Ca 2ϩ current in an HEK 293/␣ 1 G cell, elicited by depolarizations to Ϫ10 mV every 10 s. In contrast, after the addition of 8 M NNC 55-0396, switching the membrane potential from Ϫ80 to Ϫ120 mV caused an increase in the current amplitude, suggesting a partial relief of block at the more hyperpolarized holding potential. Similarly, increasing the pulse rate from 0.05 to 0.5 Hz had little effect on current amplitude without NNC (n ϭ 3) . B, steady-state inactivation curves of T-type Ca 2ϩ channel with (solid circles) and without (open circles) the presence of 8 M NNC 55-0396 were fit by the Boltzmann equation (n ϭ 6). Steady-state inactivation was determined by applying a prestimulating pulse of 1.5 s at various voltages immediately before the test pulse at Ϫ20 mV. For both A and B, currents were recorded in HEK 293/␣ 1 G cells, and the cell membrane was held at Ϫ70 mV. Selective T-Type Ca 2؉ Channel Blocker 55-0396, whereas the rate of inhibition of T-type Ca 2ϩ current was accelerated by increasing the frequency of stimulation in the presence of the drug (Fig. 5B) . Similar results of both voltage-dependent and frequency-dependent blockade were observed in four experiments.
Mass Spectrometric Analysis of NNC 55-0396-Treated INS-1 Cells. Previously, we found that mibefradil blocked both T-type and HVA Ca 2ϩ current in INS-1 cells . After entering the cells, mibefradil is broken down into metabolites. One of them is des-methoxyacetyl mibefradil, which exerts an inhibitory effect on HVA Ca 2ϩ channels by acting on the channels from inside the cell. To investigate why NNC 55-0396 and mibefradil have different effects on HVA Ca 2ϩ channels, we used mass spectrometric analysis to examine whether des-methoxyacetyl mibefradil was produced intracellularly when the cells were treated with NNC 55-0396. Figure 6A shows a section of mass spectrum of molecules in INS-1 cells that had been incubated with NNC 55-0396 for 20 min. Notably, no des-methoxyacetyl mibefradil (which peaks at 424 m/z) was detected in this preparation. This finding suggests that, unlike mibefradil, the compound NNC 55-0396 is not hydrolyzed into des-methoxyacetyl mibefradil. Thus, NNC 55-0396 does not inhibit HVA Ca 2ϩ channels as mibefradil does. The amount of NNC 55-0396 (which peaks at 492 m/z), however, increased in the cells for longer periods than 10 min as shown in Fig. 6B .
Accessibility of NNC 55-0396 on the T-Type Ca
2؉
Channel. The slow onset of NNC 55-0396 inhibition on Ttype Ca 2ϩ current and the increasing NNC 55-0396 accumulation in the cells with time suggest that this compound dissolves in or passes through the plasma membrane to exert its effect. To test this hypothesis, we examined the reversibility of the NNC 55-0396 blockade of T-type Ca 2ϩ current. Whole-cell currents were evoked in HEK 293/␣ 1 G cells by test pulses to Ϫ10 mV from a holding potential of Ϫ70 mV. After establishing a steady current, small volumes of 8 M NNC 55-0396 were delivered in close proximity to the recording cell with a quartz capillary positioned by a micromanipulator. The drug was washed out after more than a 50% inhibition of T-type Ca 2ϩ current was achieved. As shown in Fig. 7A , the blockade of the T-type Ca 2ϩ current by NNC 55-0396 was poorly reversible during a 10-min washout period in these experiments. Since the NNC 55-0396 blocks T-type Ca 2ϩ current at a relatively slow rate and is poorly reversible by washing out, the drug binding site of the channel may be within transmembrane or intracellular domains of the channel.
If the site of action of NNC 55-0396 is on the intracellular side of the membrane, we would expect that intracellular perfusion of the drug would effectively block T-type Ca 2ϩ current. To test this possibility, whole-cell currents were recorded in HEK 293/␣ 1 G cells with 8 M NNC 55-0396 added to the pipette solution. As shown in Fig. 7B , there was 5 . State-dependent inhibition of T-type Ca 2ϩ channels by NNC 55-0396. A, whole-cell Ca 2ϩ currents were measured at Ϫ10 mV when held at Ϫ120 and Ϫ80 mV, as indicated by the bar above the graph. The pulses were applied every 10 s. B, whole-cell Ca 2ϩ currents were measured at Ϫ10 mV when held at Ϫ70 mV at stimulation frequencies of 0.05 and 0.5 Hz, as indicated by the bar above the graph. NNC and the arrows indicate the time when NNC 55-0396 was perfused into the bath. no significant difference between the current in HEK 293/ ␣ 1 G cells with (n ϭ 10) and without (n ϭ 6) NNC 55-0396 included in the pipette solution. For example, at the 10-min timepoint, the p value is 0.12 with two-tailed unpaired Student's t test analysis. These data are inconsistent with the idea that the site of action of NNC 55-0396 is on the cytoplasmic face of the T-type Ca 2ϩ channel. Thus, NNC 55-0396 appears to exhibit a relatively slow and wash-resistant binding to a site, perhaps within the transmembrane domains of the channel.
Discussion
Mibefradil blocks both T-type Ca 2ϩ and HVA Ca 2ϩ channels. Although mibefradil appears to act directly on T-type channels, we previously reported that its effect on HVA channels is not direct but instead involves cell permeation and hydrolysis to an active metabolite that acts from the cytoplasmic side of the membrane . In the present study, we developed a new compound, NNC 55-0396, that has an inhibitory effect on T-type Ca 2ϩ current in HEK/ ␣ 1 G cells but is not hydrolyzed to an active metabolite and does not block HVA Ca 2ϩ currents in INS-1 cells. Thus, NNC 55-0396 is a selective inhibitor for T-type Ca 2ϩ channels. Our data also suggest that the effect of NNC 55-0396 on T-type channels is state-dependent; i.e., block is partially relieved by membrane hyperpolarization and enhanced by high-frequency channel activation.
Our previous findings suggest that the methoxyacetyl group of mibefradil is a critical determinant for binding to HVA channels since its hydrolysis is the critical step in the binding of the compound to HVA channels. In contrast, this moiety may play only a modest role in interacting with the receptor domain of T-type Ca 2ϩ channels since all three alternations-NNC 55-0395, NNC 55-0396, and NNC 55-0397-retain the capability of blocking T-type Ca 2ϩ current, although with varying potency. Our study indicates that modification in the methoxyacetyl group of mibefradil can improve its selectivity for T-type Ca 2ϩ channels over the HVA Ca 2ϩ channels without sacrificing the potency of T-type Ca 2ϩ channel antagonism. The primary objective of this study is to examine the structure-selectivity relationship of a small group of mibefradil derivatives. Therefore, we chose HEK/␣ 1 G as a clean model system. We do not know how effectively NNC 55-0396 will block other T-type Ca 2ϩ channels, nor do we know its potency on ␣ 1 G when other auxiliary subunits are present. However, we speculate that NNC 55-0396 will block ␣ 1 H and ␣ 1 I, for it has been shown that the IC 50 values of mibefradil blocking ␣ 1 G, ␣ 1 H, and ␣ 1 I are similar (Martin et al., 2000) . In summary, our findings represent an important step toward development of a specific T-type Ca 2ϩ inhibitor and thus have potentially important scientific and therapeutic implications.
